Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors
Conjupro Biotherapeutics, Inc.
Conjupro Biotherapeutics, Inc.
Pfizer
Pfizer
Mayo Clinic
Rutgers, The State University of New Jersey
Pheon Therapeutics
National Cancer Institute (NCI)
Xemed LLC
Sanofi
Novartis
Lyell Immunopharma, Inc.
M.D. Anderson Cancer Center
Black Diamond Therapeutics, Inc.
Novartis
Blueprint Medicines Corporation
Blueprint Medicines Corporation
Mirati Therapeutics Inc.
ABM Therapeutics Corporation
Inhibrx Biosciences, Inc
Emory University
Pfizer
University of California, San Francisco
Yale University
SCRI Development Innovations, LLC
Fate Therapeutics
Blueprint Medicines Corporation
Turning Point Therapeutics, Inc.
Bristol-Myers Squibb
University of California, San Francisco
Indiana University
Augusta University
Novartis
The Methodist Hospital Research Institute
University of Texas Southwestern Medical Center
Lumos Pharma
Pfizer
Abramson Cancer Center at Penn Medicine
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Pfizer
University of Pittsburgh
University of Massachusetts, Worcester
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
VA Office of Research and Development